eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2021
vol. 25
 
Share:
Send email
Share:
abstract:
Original paper

Surface mould brachytherapy in oral and oropharyngeal cancers

Leonid B. Reshko
1
,
Jeremy T. Gaskins
1
,
Jeffrey M. Bumpous
1
,
Paul A. Tennant
1
,
Zafrulla Khan
1
,
Keith Sowards
1
,
Craig L. Silverman
1
,
Neal E. Dunlap
1

  1. University of Louisville, United States
Contemp Oncol (Pozn) 2021; 25 (4): 254–263
DOI: https://doi.org/10.5114/wo.2021.111087
Online publish date: 2021/11/24
View full text Get citation
 
PlumX metrics:
Introduction
There are insufficient data on surface mold brachytherapy (SMB) in treating oral cancers. We reviewed our institutional experience to investigate the efficacy and toxicity of this treatment modality.

Material and methods
We retrospectively reviewed all the patients treated between 1989 and 2018 with high-dose-rate iridium-192 SMB for oral and oropharyngeal squamous cell carcinomas at our institution. Surface mold brachytherapy was delivered via an acrylic surface mold with 1–5 inserted catheters spaced 1 cm apart fabricated by our dental oncologist. The Kaplan-Meier product estimator was used to assess local control (LC), locoregional control (LRC), distant metastasis-free survival (DMFS), and overall survival (OS). Cox proportional hazards regression analysis was used to assess the relationship of various variables and patient outcomes.

Results
Eighteen patients met the inclusion criteria and were evaluated. Indications for treatment were primary tumor (n = 13), local recurrence (2), locoregional recurrence (1), and oligometastatic disease (1). Ten patients received SMB alone and 8 received external beam radiotherapy with an SMB boost. The acute toxicity outcomes were as follows: no toxicity (n = 1), grade 1 (7), grade 2 (9), and grade 3 (1). Late effects were rare, only occurring in 3 patients. The one- and two-year LC were 81% and 68%, LRC 77% and 64%, DMFS 81% and 81%, and OS 77% and 46%.

Conclusions
Surface mold brachytherapy is a viable modality as either primary or boost treatment for superficial oral cancers. In our patients, this treatment method has a low toxicity profile and resulted in reasonable LC.

keywords:

surface mold brachytherapy, head and neck cancer, brachytherapy, oral cancer, oropharyngeal cancer, head and neck cancer
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.